Utility of interrupting antiretroviral treatment before HIV drug resistance testing in patients with persistently detectable low-level viremia.
Sirvent
Juan Luis Gûmez
JL
Socas
Marìa Mar Alonso
MM
Calzadilla
Carlos Hernndez
CH
Lirola
Ana M Lûpez
AM
Valls
Marìa Remedios Aleman
MR
D000328:Adult; D044966:Anti-Retroviral Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D012321:DNA-Directed RNA Polymerases / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D016333:HIV Protease / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D014766:Viremia
D044966:Anti-Retroviral Agents; D012321:DNA-Directed RNA Polymerases; D016333:HIV Protease